These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 30893088)

  • 21. Acupuncture-Induced Analgesia: The Role of Microglial Inhibition.
    Lin L; Skakavac N; Lin X; Lin D; Borlongan MC; Borlongan CV; Cao C
    Cell Transplant; 2016; 25(4):621-8. PubMed ID: 26849399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Update on pain management in sickle cell disease.
    Ballas SK
    Hemoglobin; 2011; 35(5-6):520-9. PubMed ID: 21910604
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Developing an Implementation Blueprint for the NIH HEAL Initiative GRACE Trial: Perspectives on Acupuncture and Guided Relaxation for Chronic Sickle Cell Disease Pain.
    Knisely MR; Rivera E; deMartelly VA; Abdulkadir A; Doorenbos AZ; Ezenwa MO; Molokie RE; Li H; Shah N; Schlaeger JM; Patil CL
    J Integr Complement Med; 2023 Oct; 29(10):683-688. PubMed ID: 37184905
    [No Abstract]   [Full Text] [Related]  

  • 24. Acupuncture for pain management in children with sickle cell disease.
    Mahmood LA; Reece-Stremtan S; Idiokitas R; Martin B; Margulies S; Hardy SJ; Bost JE; Darbari DS
    Complement Ther Med; 2020 Mar; 49():102287. PubMed ID: 32147045
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Leukotriene pathway in sickle cell disease: a potential target for directed therapy.
    Knight-Perry J; DeBaun MR; Strunk RC; Field JJ
    Expert Rev Hematol; 2009 Feb; 2(1):57-68. PubMed ID: 21082995
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pediatric residents' perceived barriers to opioid use in sickle cell disease pain management.
    Fearon A; Marsh A; Kim J; Treadwell M
    Pediatr Blood Cancer; 2019 Feb; 66(2):e27535. PubMed ID: 30387290
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pain management and quality of life in sickle cell disease.
    Howard J; Thomas VJ; Rawle HM
    Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):347-52. PubMed ID: 19670995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dexmedetomidine ameliorates nocifensive behavior in humanized sickle cell mice.
    Calhoun G; Wang L; Almeida LE; Kenyon N; Afsar N; Nouraie M; Finkel JC; Quezado ZM
    Eur J Pharmacol; 2015 May; 754():125-33. PubMed ID: 25724786
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of oxidative stress in the pathogenesis of sickle cell disease.
    Chirico EN; Pialoux V
    IUBMB Life; 2012 Jan; 64(1):72-80. PubMed ID: 22131167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The fucosylation inhibitor, 2-fluorofucose, inhibits vaso-occlusion, leukocyte-endothelium interactions and NF-ĸB activation in transgenic sickle mice.
    Belcher JD; Chen C; Nguyen J; Abdulla F; Nguyen P; Nguyen M; Okeley NM; Benjamin DR; Senter PD; Vercellotti GM
    PLoS One; 2015; 10(2):e0117772. PubMed ID: 25706118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sickle cell disease patients' perceptions of emergency department pain management.
    Porter J; Feinglass J; Artz N; Hafner J; Tanabe P
    J Natl Med Assoc; 2012; 104(9-10):449-54. PubMed ID: 23342819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dexmedetomidine as an Adjuvant to Analgesic Strategy During Vaso-Occlusive Episodes in Adolescents with Sickle-Cell Disease.
    Sheehy KA; Finkel JC; Darbari DS; Guerrera MF; Quezado ZM
    Pain Pract; 2015 Nov; 15(8):E90-7. PubMed ID: 26205912
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of a clinical pathway to improve the acute management of vaso-occlusive crisis pain in pediatric sickle cell disease.
    Ender KL; Krajewski JA; Babineau J; Tresgallo M; Schechter W; Saroyan JM; Kharbanda A
    Pediatr Blood Cancer; 2014 Apr; 61(4):693-6. PubMed ID: 24249617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted nanoparticles that mimic immune cells in pain control inducing analgesic and anti-inflammatory actions: a potential novel treatment of acute and chronic pain condition.
    Hua S; Cabot PJ
    Pain Physician; 2013; 16(3):E199-216. PubMed ID: 23703419
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Critical role of C5a in sickle cell disease.
    Vercellotti GM; Dalmasso AP; Schaid TR; Nguyen J; Chen C; Ericson ME; Abdulla F; Killeen T; Lindorfer MA; Taylor RP; Belcher JD
    Am J Hematol; 2019 Mar; 94(3):327-337. PubMed ID: 30569594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies.
    Noubouossie D; Key NS; Ataga KI
    Blood Rev; 2016 Jul; 30(4):245-56. PubMed ID: 26776344
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pain Management Issues as Part of the Comprehensive Care of Patients with Sickle Cell Disease.
    Lakkakula BVKS; Sahoo R; Verma H; Lakkakula S
    Pain Manag Nurs; 2018 Dec; 19(6):558-572. PubMed ID: 30076112
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Soluble Fas/FasL ratio as a marker of vasculopathy in children and adolescents with sickle cell disease.
    Adly AA; Ismail EA; Andrawes NG; Mahmoud MM; Eladawy R
    Cytokine; 2016 Mar; 79():52-8. PubMed ID: 26765484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel Sickle Cell Disease Therapies: Targeting Pathways Downstream of Sickling.
    Morrone K; Mitchell WB; Manwani D
    Semin Hematol; 2018 Apr; 55(2):68-75. PubMed ID: 30616808
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sickle cell disease pain management in adolescents: a literature review.
    Wilson BH; Nelson J
    Pain Manag Nurs; 2015 Apr; 16(2):146-51. PubMed ID: 25175555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.